Abstract
Heart failure accounts for more deaths in the United States than any other detrimental human pathology. Recently, repairing the heart after seemingly irreversible injury leading to heart failure appears to have come within reach. Cellular cardiomyoplasty, transplanting viable cell alternatives into the diseased myocardium, has emerged as a promising possible solution. Translating this approach from the laboratory to the clinic, however, has been met with several challenges, leaving many questions unanswered. This review assesses the state of investigation of several progenitor cell sources, including induced pluripotent stem cells, embryonic stem cells, bone marrow stem cells, adipose-derived adult stem cells, amniotic fluid stem cells, skeletal muscle progenitors, induced pluripotent stem cells and cardiac progenitors. Several current roadblocks to maximum success are discussed. These include understanding the need for cardiomyocyte differentiation, appreciating the role of paracrine factors, and addressing the low engraftment rates using current techniques. Tissue engineering strategies to address these obstacles and to help maximize cellular cardiomyoplasty success are reviewed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 210-223 |
| Number of pages | 14 |
| Journal | Current Stem Cell Research and Therapy |
| Volume | 4 |
| Issue number | 3 |
| State | Published - 2009 |
| Externally published | Yes |
Fingerprint
Keywords
- Cell delivery
- Differentiation
- Myocardial infarction
- Paracrine factors
- Progenitor cell
- Tissue engineering
ASJC Scopus subject areas
- Medicine (miscellaneous)
Cite this
Lost in translation : What is limiting cardiomyoplasty and can tissue engineering help? / Simpson, David L.; Dudley, Samuel C.
In: Current Stem Cell Research and Therapy, Vol. 4, No. 3, 2009, p. 210-223.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Lost in translation
T2 - What is limiting cardiomyoplasty and can tissue engineering help?
AU - Simpson, David L.
AU - Dudley, Samuel C.
PY - 2009
Y1 - 2009
N2 - Heart failure accounts for more deaths in the United States than any other detrimental human pathology. Recently, repairing the heart after seemingly irreversible injury leading to heart failure appears to have come within reach. Cellular cardiomyoplasty, transplanting viable cell alternatives into the diseased myocardium, has emerged as a promising possible solution. Translating this approach from the laboratory to the clinic, however, has been met with several challenges, leaving many questions unanswered. This review assesses the state of investigation of several progenitor cell sources, including induced pluripotent stem cells, embryonic stem cells, bone marrow stem cells, adipose-derived adult stem cells, amniotic fluid stem cells, skeletal muscle progenitors, induced pluripotent stem cells and cardiac progenitors. Several current roadblocks to maximum success are discussed. These include understanding the need for cardiomyocyte differentiation, appreciating the role of paracrine factors, and addressing the low engraftment rates using current techniques. Tissue engineering strategies to address these obstacles and to help maximize cellular cardiomyoplasty success are reviewed.
AB - Heart failure accounts for more deaths in the United States than any other detrimental human pathology. Recently, repairing the heart after seemingly irreversible injury leading to heart failure appears to have come within reach. Cellular cardiomyoplasty, transplanting viable cell alternatives into the diseased myocardium, has emerged as a promising possible solution. Translating this approach from the laboratory to the clinic, however, has been met with several challenges, leaving many questions unanswered. This review assesses the state of investigation of several progenitor cell sources, including induced pluripotent stem cells, embryonic stem cells, bone marrow stem cells, adipose-derived adult stem cells, amniotic fluid stem cells, skeletal muscle progenitors, induced pluripotent stem cells and cardiac progenitors. Several current roadblocks to maximum success are discussed. These include understanding the need for cardiomyocyte differentiation, appreciating the role of paracrine factors, and addressing the low engraftment rates using current techniques. Tissue engineering strategies to address these obstacles and to help maximize cellular cardiomyoplasty success are reviewed.
KW - Cell delivery
KW - Differentiation
KW - Myocardial infarction
KW - Paracrine factors
KW - Progenitor cell
KW - Tissue engineering
UR - http://www.scopus.com/inward/record.url?scp=74849092822&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74849092822&partnerID=8YFLogxK
M3 - Review article
C2 - 19492979
AN - SCOPUS:74849092822
VL - 4
SP - 210
EP - 223
JO - Current Stem Cell Research and Therapy
JF - Current Stem Cell Research and Therapy
SN - 1574-888X
IS - 3
ER -